In this video, health-care analysts David Williamson and Max Macaluso discuss four big headlines impacting some of the most popular stocks in the space. Watch and find out what it all means for investors.

 

The biotech space can make or destroy investors overnight, and Amarin, with its potential blockbuster drug, will be no different. The company has huge potential, but don't invest today before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here to keep reading. 

David Williamson owns shares of Amarin Corporation, but he holds no other position in any company mentioned. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services recommend Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.